193 related articles for article (PubMed ID: 10778976)
21. Expression of PC cell-derived growth factor and vascular endothelial growth factor in esophageal squamous cell carcinoma and their clinicopathologic significance.
Chen XY; Li JS; Liang QP; He DZ; Zhao J
Chin Med J (Engl); 2008 May; 121(10):881-6. PubMed ID: 18706200
[TBL] [Abstract][Full Text] [Related]
22. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas.
Yamabuki T; Takano A; Hayama S; Ishikawa N; Kato T; Miyamoto M; Ito T; Ito H; Miyagi Y; Nakayama H; Fujita M; Hosokawa M; Tsuchiya E; Kohno N; Kondo S; Nakamura Y; Daigo Y
Cancer Res; 2007 Mar; 67(6):2517-25. PubMed ID: 17363569
[TBL] [Abstract][Full Text] [Related]
23. Use of an antibody against the soluble interleukin 2 receptor alpha subunit can modulate the stability and biodistribution of interleukin-2.
Kobayashi H; Tagaya Y; Han ES; Kim IS; Le N; Paik CH; Pastan I; Nelson DL; Waldmann TA; Carrasquillo JA
Cytokine; 1999 Dec; 11(12):1065-75. PubMed ID: 10623432
[TBL] [Abstract][Full Text] [Related]
24. Serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a prognostic tumor marker in patients with esophageal squamous cell carcinoma.
Nabeya Y; Shimada H; Okazumi S; Matsubara H; Gunji Y; Suzuki T; Ochiai T
Cancer; 2002 Feb; 94(4):940-9. PubMed ID: 11920462
[TBL] [Abstract][Full Text] [Related]
25. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
[TBL] [Abstract][Full Text] [Related]
26. High serum soluble E-selectin levels are associated with postoperative haematogenic recurrence in esophageal squamous cell carcinoma patients.
Shimada Y; Maeda M; Watanabe G; Imamura M
Oncol Rep; 2003; 10(4):991-5. PubMed ID: 12792758
[TBL] [Abstract][Full Text] [Related]
27. Association of matrilysin-2 (MMP-26) expression with tumor progression and activation of MMP-9 in esophageal squamous cell carcinoma.
Yamamoto H; Vinitketkumnuen A; Adachi Y; Taniguchi H; Hirata T; Miyamoto N; Nosho K; Imsumran A; Fujita M; Hosokawa M; Hinoda Y; Imai K
Carcinogenesis; 2004 Dec; 25(12):2353-60. PubMed ID: 15333466
[TBL] [Abstract][Full Text] [Related]
28. An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo.
Ito T; Hashimoto Y; Tanaka E; Kan T; Tsunoda S; Sato F; Higashiyama M; Okumura T; Shimada Y
Clin Cancer Res; 2006 Feb; 12(4):1308-16. PubMed ID: 16489088
[TBL] [Abstract][Full Text] [Related]
29. [Serum soluble interleukin 2 receptor in patients with squamous epithelial carcinomas of the upper aerodigestive tract].
Gottschlich S; Werner JA; Lippert BM; Görögh T; Maune S; Rudert H
Laryngorhinootologie; 1995 Aug; 74(8):508-11. PubMed ID: 7575904
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of serum biological markers in patients with hepatocellular carcinoma.
Parasole R; Izzo F; Perrone F; Pignata S; Galati MG; Leonardi E; Castiglione F; Orlando R; Castello G; Esposito G; Gallo C; Daniele B
Clin Cancer Res; 2001 Nov; 7(11):3504-9. PubMed ID: 11705869
[TBL] [Abstract][Full Text] [Related]
31. Reduced expression of p63 has prognostic implications for patients with esophageal squamous cell carcinoma.
Takahashi Y; Noguchi T; Takeno S; Kimura Y; Okubo M; Kawahara K
Oncol Rep; 2006 Feb; 15(2):323-8. PubMed ID: 16391849
[TBL] [Abstract][Full Text] [Related]
32. Prognostic role of PGE2 receptor EP2 in esophageal squamous cell carcinoma.
Kuo KT; Wang HW; Chou TY; Hsu WH; Hsu HS; Lin CH; Wang LS
Ann Surg Oncol; 2009 Feb; 16(2):352-60. PubMed ID: 19050969
[TBL] [Abstract][Full Text] [Related]
33. Clinical and prognostic significance of RhoA and RhoC gene expression in esophageal squamous cell carcinoma.
Faried A; Faried LS; Usman N; Kato H; Kuwano H
Ann Surg Oncol; 2007 Dec; 14(12):3593-601. PubMed ID: 17896152
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C.
Kitaoka S; Shiota G; Kawasaki H
Hepatogastroenterology; 2003; 50(53):1569-74. PubMed ID: 14571788
[TBL] [Abstract][Full Text] [Related]
35. Soluble interleukin-2 receptor in serum of patients with esophageal carcinoma.
Jabłońska E; Kozłowski M; Pietruska Z; Furman M
Neoplasma; 1994; 41(6):315-8. PubMed ID: 7870214
[TBL] [Abstract][Full Text] [Related]
36. Microsatellite instability and clinicopathological features in esophageal squamous cell cancer.
Matsumoto Y; Nagasaka T; Kambara T; Hoshizima N; Murakami J; Sasamoto H; Hosokawa M; Naomoto Y; Isozaki H; Shimizu K; Tanaka N; Matsubara N
Oncol Rep; 2007 Nov; 18(5):1123-7. PubMed ID: 17914562
[TBL] [Abstract][Full Text] [Related]
37. [Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squamous cell carcinoma patients--a report of 43 cases].
Wang XS; Liu MZ; Zhang CQ; Cai L; Cui NJ
Ai Zheng; 2006 Nov; 25(11):1428-32. PubMed ID: 17094915
[TBL] [Abstract][Full Text] [Related]
38. Serum levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) as a predictor of outcome in brucellosis.
Makis AC; Galanakis E; Hatzimichael EC; Papadopoulou ZL; Siamopoulou A; Bourantas KL
J Infect; 2005 Oct; 51(3):206-10. PubMed ID: 16230217
[TBL] [Abstract][Full Text] [Related]
39. Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma.
Takatori H; Natsugoe S; Okumura H; Matsumoto M; Uchikado Y; Setoyama T; Sasaki K; Tamotsu K; Owaki T; Ishigami S; Aikou T
Eur J Surg Oncol; 2008 Apr; 34(4):397-402. PubMed ID: 17553653
[TBL] [Abstract][Full Text] [Related]
40. Correlation between RhoA overexpression and tumour progression in esophageal squamous cell carcinoma.
Faried A; Nakajima M; Sohda M; Miyazaki T; Kato H; Kuwano H
Eur J Surg Oncol; 2005 May; 31(4):410-4. PubMed ID: 15837049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
